Spotlight On... Valeant's meltdown claims another top exec, this time at shareholder Sequoia; Gilead CEO vows to fight Merck's hep C patent win; NJ judge consolidates compulsive gambling claims against Abilify; and more...

Sequoia Fund chief Robert Goldfarb bowed out of his post Wednesday after his big bet on Valeant Pharmaceuticals ($VRX) turned up sour. One of the embattled drugmaker's biggest shareholders, Sequoia at one point had 30% of its capital tied up in Valeant, MarketWatch reports. Report

@FiercePharma: Roslin turns to business with new animal health venture. FierceAnimalHealth article | Follow @FiercePharma

@CarlyHFierce: Lilly's new psoriasis med Taltz sets up head-to-head with Novartis' Cosentyx. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Gilead Sciences ($GILD) CEO John Milligan confirmed that his company will appeal a patent decision that could deliver royalties to Merck & Co. ($MRK) on Gilead's blockbuster hep C meds Sovaldi and Harvoni. Report

> A New Jersey judge consolidated pretrial work on suits alleging that the Bristol-Myers Squibb ($BMY) and Otsuka antipsychotic drug Abilify triggered patients' compulsive gambling. Report

> Sun Pharma and AstraZeneca ($AZN) teamed up on a distribution deal for AZ's diabetes drug Onglyza in Sun's home country of India. Report

> A group of indirect purchasers can move forward with their pay-for-delay claims against GlaxoSmithKline ($GSK) and Teva Pharmaceutical ($TEVA), a New Jersey judge said, citing a previous Third Circuit decision in a similar case. Report

Medical Device News

@FierceMedDev: Dx Digest: Quanterix reels in $46M for international expansion and more. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: NICE gives initial thumbs-down to Vertex's CF combo med Orkambi, citing costs. Story | Follow @EmilyWFierce

> Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Story

Biotech News

@FierceBiotech: From Chutes & Laddrers: Valeant CEO Mike Pearson out as embattled drugmaker seeks new leadership. More | Follow @FierceBiotech

@JohnCFierce: Bayer looks to protect blockbuster Eylea franchise with $130M Regeneron pact. News | Follow @JohnCFierce

> PTC Therapeutics to cull its ranks after FDA spurns Duchenne drug. Story

> The 'Uber for experiments' group Science Exchange raises $25M. News

> Portola plunges as PhIII blood thinner misses key goal in head-to-head comparison study. Article

> Atlantic Healthcare plots opening of NC office as influence of ex-Salix team grows. More

CRO News

> Global CRO market expected to rocket to $59B by 2020. Story

> NovAliX signs EM-based analysis deal with FEI. More

> Precision for Medicine broadens cancer trial offering with ACT Oncology buy. Report

> Quintiles, Mitsui and investors pay toward a new $866M development fund. Story

> BioPharmaSpec plots Asian expansion with a focus on biosimilars. Article

Pharma Manufacturing News

> Seqirus reviews its manpower needs as it integrates Novartis flu operations. Article

> Vetter's building binge continues with ground-breaking for another Schuetzenstrasse facility. More

> China, in typical fashion, arrests dozens as drug oversight draws attention. Story

> First FDA-approved 3-D manufactured drug hits the market. Item

> Cadila faces new regulatory problems as WHO piles on the pain. More

Pharma Asia News

> Zhejiang Medicine at work with Ambrx on PhI breast cancer candidate. Story

> Ally Bridge keeps cash flowing in $155M private placement in Tesaro. Report

> Taiwan's OBI trial results dispute snares top science research executive. More

> Novartis settlement with U.S. SEC on China bribes one in a string. Story

> China in overdrive on illegal vaccine sales probe. Article

And Finally... Johnson & Johnson ($JNJ) added to its popular collection of "7-Minute" apps with a new version directed at expectant and new mothers. Report

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.